CD44 and prostate neoplasm: CD133 has been widely used, usually in combination with other stem cell markers such as CD44 and α2β1 integrin, to isolate cancer stem cells from prostate tumors with different Gleason grade, including cells from both primary and metastatic lesions [38,39,40,41].